KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Working Capital Changes (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Other Working Capital Changes for 16 consecutive years, with -$307000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes fell 35.24% year-over-year to -$307000.0, compared with a TTM value of $111000.0 through Sep 2025, up 105.22%, and an annual FY2024 reading of $108000.0, up 105.4% over the prior year.
  • Other Working Capital Changes was -$307000.0 for Q3 2025 at TherapeuticsMD, up from -$496000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.0 million in Q2 2022 and bottomed at -$1.4 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$76210.5, with a median of -$18000.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes surged 1916.67% in 2021, then tumbled 948.33% in 2024.
  • Year by year, Other Working Capital Changes stood at $399000.0 in 2021, then plummeted by 33.83% to $264000.0 in 2022, then tumbled by 618.94% to -$1.4 million in 2023, then soared by 162.99% to $863000.0 in 2024, then plummeted by 135.57% to -$307000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for TXMD at -$307000.0 in Q3 2025, -$496000.0 in Q2 2025, and $51000.0 in Q1 2025.